<DOC>
	<DOC>NCT02032277</DOC>
	<brief_summary>This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC.</brief_summary>
	<brief_title>A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Veliparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1. Histologically confirmed invasive breast cancer by core needle or incisional biopsy (excisional biopsy is not allowed). Tumors must be clinical stage T23 N02 or T1 N12 per AJCC Staging Edition 7 or clinical stage T23 N02 or T1 N12 by physical exam or radiologic studies. 2. Documented Breast Cancer Gene (BRCA) germline mutation testing. 3. Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor (HER)2negative (triplenegative) cancer of the breast. 4. ECOG Performance status of 0 to 1. 5. Women must be determined to be not of childbearing potential (surgically sterile, or postmenopausal defined as amenorrheic for at least 12 months) by the Investigator OR they must have a negative serum pregnancy test prior to randomization. 1. Previous anticancer treatment (cytotoxic chemotherapy, immunotherapy, biologic therapy radiotherapy or investigational agents) with therapeutic intent for current breast cancer. 2. Previous treatment with carboplatin, paclitaxel, doxorubicin, cyclophosphamide and a Poly(ADPribose)Polymerase (PARP) inhibitor. 3. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Subjects must have discontinued use of such agents prior to beginning study treatment. 4. A history of seizure within 12 months prior to study entry. 5. Preexisting neuropathy from any cause in excess of Grade 1.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Oncology</keyword>
	<keyword>United States Oncology - 12152</keyword>
	<keyword>Alliance - AFT-04</keyword>
	<keyword>Triple negative breast cancer</keyword>
	<keyword>National Surgical Adjuvant Breast and Bowel Project - B-56-I</keyword>
	<keyword>Grupo Español de Investigación en Cáncer de Mama - GEICAM/2014-02</keyword>
	<keyword>German Breast Group - GBG 81</keyword>
</DOC>